Insulet Recalls Omnipod 5 Insulin Pods After 18 Serious Adverse Events Linked to Internal Tubing Defect
Insulet has initiated a voluntary recall of certain Omnipod 5 insulin pump pods after a manufacturing defect caused insulin to leak inside the device rather than reaching patients, leading to 18 serious adverse events including hospitalizations for diabetic ketoacidosis.
Overview
Insulet Corporation has initiated a voluntary medical device correction for certain lots of its Omnipod 5 automated insulin delivery pods distributed in the United States, after identifying a manufacturing defect that can cause insulin to leak inside the device rather than being delivered to the patient. The company disclosed that the FDA has received 18 reports of serious adverse events, including hospitalizations for diabetic ketoacidosis, though no deaths have been reported, according to the FDA’s recall notice.
The correction, announced on March 12 and published by the FDA on March 13, affects approximately 1.5 percent of Omnipod 5’s annual global pod production. Insulet expects to incur up to $40 million in costs related to the recall this year.
What We Know
The defect involves a small tear in the internal tubing that delivers insulin from the pod’s reservoir into the patient’s body. When the tubing is compromised, insulin can leak inside the pod instead of being fully infused subcutaneously, resulting in under-delivery of the drug. Patients who receive insufficient insulin may experience elevated blood glucose levels, and in the most severe cases, prolonged hyperglycemia can progress to diabetic ketoacidosis, a potentially life-threatening condition that requires emergency medical treatment, as detailed in the FDA’s early alert.
Insulet identified the issue through its ongoing product monitoring processes. The affected lots represent a narrow slice of production, and all other Omnipod 5 pods and Omnipod products remain unaffected. The correction does not impact continuous glucose monitoring systems or CGM readings used alongside the pods, according to Fierce Biotech’s reporting.
The company has directed users to check their pod lot numbers at omnipod.com/check-pods and to discontinue use of any pod from an affected lot immediately. Replacement pods are available at no cost, and Insulet’s product support line is operating around the clock at 1-800-641-2049.
Insulet has stated that it continues to manufacture and ship Omnipod 5 pods and does not anticipate disruption to customer shipments, product availability, or new patient starts. The company has not changed its revenue growth guidance of 20 to 22 percent for 2026 on a constant currency basis.
What We Don’t Know
Insulet has not publicly disclosed the specific manufacturing root cause of the tubing tear or identified which production facility or process step introduced the defect. The exact number of affected pods and the full list of lot numbers have not been made publicly available beyond the company’s online lookup tool.
Whether additional lots will be added to the recall as the investigation continues has not been addressed. The FDA’s early alert, issued on March 18, did not specify a formal recall classification, though the agency is tracking the correction through its medical device safety database.
It is also unclear whether any of the 18 serious adverse events involved patients whose automated insulin delivery algorithms failed to alert them to the under-delivery, or whether the Omnipod 5 system’s integration with continuous glucose monitors provided timely warnings of rising blood glucose levels.
Analysis
The Omnipod 5 is Insulet’s flagship product and the first tubeless automated insulin delivery system cleared by the FDA, integrating an insulin pump with continuous glucose monitoring to adjust basal insulin delivery automatically. The device has become a central platform in diabetes management, particularly among patients who prefer a discreet, patch-style pump over traditional tubed systems.
For a company whose revenue is built almost entirely around a single product line, even a limited recall carries outsized significance. Insulet’s stock dropped approximately 7 percent following the announcement, reflecting investor sensitivity to quality issues in a device that patients depend on continuously. Analyst Mike Kratky of Leerink Partners described the recall as “an unwelcome development” but said he does not expect a significant shift in market share or commercial patterns, according to Fierce Biotech.
The $40 million estimated cost, while material, represents a fraction of Insulet’s annual revenue, which exceeded $2 billion in fiscal 2025. The company’s decision to maintain its growth guidance suggests confidence that the correction will remain contained to the identified lots.
The broader context is a diabetes device market undergoing rapid expansion and consolidation. Omnipod 5 competes with Medtronic’s MiniMed 780G, Tandem Diabetes Care’s t:slim X2 with Control-IQ, and Beta Bionics’ iLet bionic pancreas system. Each platform depends on patient trust in continuous, automated drug delivery — a trust that manufacturing defects, however isolated, can erode. How quickly Insulet resolves the root cause and communicates its findings will likely determine whether this recall remains a manageable episode or becomes a more lasting concern for the company and its users.